What POTS really looks like at the bedside
POTS patients have a jumpy heart rate on standing. Blood pressure usually holds steady.
That combination is important. If the nerves truly failed, blood pressure would drop. It doesn't.
So the heart is not broken. It is working overtime.
The rescue system nobody talks about
Think of your circulation like water in a garden hose. When you stand up, gravity pulls blood into your legs and belly.
Your body needs to push that blood back up to your brain. It does this by tightening blood vessels and speeding up the heart.
If the hose is half-empty, or if the veins don't squeeze well, the heart has to pump faster to keep the brain supplied.
In many POTS patients, the racing heart is not the disease. It's the body's alarm.
Old view versus new view
The old view: POTS equals dysautonomia equals nerve failure. Treat the heart rate with medications like beta blockers or ivabradine.
The new view this review pushes: most POTS is compensatory. The heart is racing because something upstream is off.
That something could be low blood volume, blood pooling in the legs, weak vessel tightening, or deconditioning from long bed rest or illness.
Why the wording matters
Words shape treatment. If a patient is told their autonomic nerves have failed, both doctor and patient often drift toward drugs that slow the heart.
Slowing the heart removes the alarm. It does not fix what set off the alarm.
Worse, it can leave the brain with even less blood flow. Some patients feel sicker after starting heart-rate drugs.
A better way to sort POTS patients
The review proposes grouping patients by what is actually driving their tachycardia. The main buckets are:
Low-preload or pooling type, where venous return is the problem. These patients may improve with salt, fluids, compression garments, and tilt training.
Neuropathic type, where small nerves in the legs don't squeeze vessels well. Different treatment targets here.
Hyperadrenergic type, where the body pours out too much adrenaline. Medications may help, but the cause still needs hunting.
Immune-associated type, often appearing after viral illness like COVID.
Secondary type, linked to structural heart issues or problems with spinal fluid pressure.
The deconditioning piece
Many POTS patients have been sick or bedbound for weeks or months before symptoms begin. Muscles weaken. Blood volume shrinks. Veins lose tone.
Even healthy astronauts get POTS-like symptoms after space flight, for exactly this reason.
Gentle, graded exercise, often starting with recumbent cycling or swimming, helps a large share of patients. But recovery is slow.
How this could change care
Instead of reaching first for a pill, doctors would ask: why is this heart racing?
They might check blood volume, review recent illnesses, look for signs of small-fiber neuropathy, and screen for immune triggers.
Treatment would target the driver, not just the number on the heart monitor. Heart-rate medicines would still have a role, but as one option among many, not the default.
Expert perspective in context
This review does not deny that POTS is real or disabling. Patients often live with brain fog, fatigue, and daily dizziness for years.
The point is more respectful, not less. Calling the tachycardia a signal rather than a failure gives doctors more to work with and gives patients more plausible paths forward.
Many POTS specialists already practice this way. This review tries to push it into mainstream cardiology.
If you have POTS, the review does not ask you to stop any current treatment. Talk with your clinician before changing anything.
But it may be worth asking: what specifically is driving my tachycardia? Have we looked at blood volume, pooling, deconditioning, or recent viral triggers?
Knowing your POTS subtype may open doors to treatments that better match your body.
The honest limitations
This is a narrative, hypothesis-driven review, not a new trial. It organizes existing evidence into a framework. It does not prove that one approach beats another in head-to-head testing.
Subtypes are proposed, not definitively validated. Different experts draw the lines differently.
The real test will come from trials that group patients by subtype and measure outcomes. Those studies are starting but will take years.
In the meantime, expect more conversations in clinics about what kind of POTS a patient has, rather than whether they have POTS at all.
